Diagnosis of patients included in the NHL-B1 trial after histopathologic review
. | All, % . | CHOP-21, % . | CHOP-14, % . | CHOEP-21, % . | CHOEP-14, % . |
|---|---|---|---|---|---|
| B-cell | 85.8 | 89.2 | 83.6 | 83.3 | 87.0 |
| Diffuse large | 59.8 | 60.2 | 57.5 | 58.3 | 62.6 |
| Centroblastic | 46.0 | 50.5 | 44.1 | 42.7 | 46.3 |
| Immunoblastic | 4.9 | 3.4 | 4.7 | 5.9 | 5.6 |
| Anaplastic | 2.4 | 0.6 | 2.3 | 3.2 | 3.4 |
| T-cell rich | 2.3 | 1.7 | 2.9 | 2.7 | 1.7 |
| NOS | 4.2 | 4.0 | 3.5 | 3.8 | 5.6 |
| Mediastinal B cell | 3.0 | 4.0 | 3.5 | 1.1 | 3.4 |
| Follicular grade 3b | 8.8 | 7.9 | 9.8 | 10.3 | 7.3 |
| Burkitt lymphoma | 1.4 | 2.3 | 1.2 | 2.2 | 0.0 |
| Aggressive marginal zone | 1.4 | 1.7 | 0.6 | 1.1 | 2.3 |
| Unspecified for technical reasons* | 5.4 | 6.3 | 3.5 | 4.9 | 6.8 |
| NOS | 6.0 | 6.8 | 7.5 | 5.4 | 4.6 |
| T-cell | 13.7 | 10.8 | 15.8 | 16.6 | 12.0 |
| Anaplastic large cell | 9.4 | 7.9 | 9.9 | 10.8 | 9.1 |
| Lymphoblastic | 0.4 | 0.6 | 1.2 | 0.0 | 0.0 |
| Peripheral T, unspecified | 2.5 | 1.7 | 3.5 | 4.2 | 0.6 |
| Angioimmunoblastic | 0.1 | 0.0 | 0.0 | 0.0 | 0.6 |
| Extranodal NK/T, nasal type | 0.7 | 0.0 | 1.2 | 1.1 | 0.6 |
| NOS | 0.6 | 0.6 | 0.0 | 0.5 | 1.1 |
| Lymphoblastic, NOS | 0.4 | 0.0 | 0.6 | 0.0 | 1.1 |
. | All, % . | CHOP-21, % . | CHOP-14, % . | CHOEP-21, % . | CHOEP-14, % . |
|---|---|---|---|---|---|
| B-cell | 85.8 | 89.2 | 83.6 | 83.3 | 87.0 |
| Diffuse large | 59.8 | 60.2 | 57.5 | 58.3 | 62.6 |
| Centroblastic | 46.0 | 50.5 | 44.1 | 42.7 | 46.3 |
| Immunoblastic | 4.9 | 3.4 | 4.7 | 5.9 | 5.6 |
| Anaplastic | 2.4 | 0.6 | 2.3 | 3.2 | 3.4 |
| T-cell rich | 2.3 | 1.7 | 2.9 | 2.7 | 1.7 |
| NOS | 4.2 | 4.0 | 3.5 | 3.8 | 5.6 |
| Mediastinal B cell | 3.0 | 4.0 | 3.5 | 1.1 | 3.4 |
| Follicular grade 3b | 8.8 | 7.9 | 9.8 | 10.3 | 7.3 |
| Burkitt lymphoma | 1.4 | 2.3 | 1.2 | 2.2 | 0.0 |
| Aggressive marginal zone | 1.4 | 1.7 | 0.6 | 1.1 | 2.3 |
| Unspecified for technical reasons* | 5.4 | 6.3 | 3.5 | 4.9 | 6.8 |
| NOS | 6.0 | 6.8 | 7.5 | 5.4 | 4.6 |
| T-cell | 13.7 | 10.8 | 15.8 | 16.6 | 12.0 |
| Anaplastic large cell | 9.4 | 7.9 | 9.9 | 10.8 | 9.1 |
| Lymphoblastic | 0.4 | 0.6 | 1.2 | 0.0 | 0.0 |
| Peripheral T, unspecified | 2.5 | 1.7 | 3.5 | 4.2 | 0.6 |
| Angioimmunoblastic | 0.1 | 0.0 | 0.0 | 0.0 | 0.6 |
| Extranodal NK/T, nasal type | 0.7 | 0.0 | 1.2 | 1.1 | 0.6 |
| NOS | 0.6 | 0.6 | 0.0 | 0.5 | 1.1 |
| Lymphoblastic, NOS | 0.4 | 0.0 | 0.6 | 0.0 | 1.1 |
Patient populations are as follows: all, N = 710; CHOP-21, n = 176; CHOP-14, n = 172; CHOEP-21, n = 185; and CHOEP-14, n = 177. NOS indicates not otherwise specified; NK, natural killer (cell).
Diagnosis of aggressive B-cell lymphoma was confirmed on pathology review; however, due to quality or quantity of the biopsy material, a further subclassification was not possible.